Epidemiology of Antimicrobial Resistance of S. aureus Isolated from ICU Patients in Russia: Results of Prospective Multicenter Study | CMAC

Epidemiology of Antimicrobial Resistance of S. aureus Isolated from ICU Patients in Russia: Results of Prospective Multicenter Study

Clinical Microbiology and Antimicrobial Chemotherapy. 2008; 10(4):333-344

​ Dekhnich A.V., Nikulin A.A., Ryabkova E.L., Krechikova O.I., Sukhorukova M.V., Kozlov R.S., ROSNET Study Group
Staphylococcus aureus ICU resistance nosocomial infections MRSA
Section
Antimicrobial Resistance
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2008; 10(4):333-344

Objective.

To determine in vitro activity of antimicrobials against S. aureus isolated from ICU patients in different regions of Russia.

Materials and Methods.

A total of 998 clinical strains of S.aureus isolated in 2004–2005 from 998 patients hospitalized in ICU of 32 medical institutions in different parts of Russia. Susceptibility to 16 antimicrobials was determined by agar dilution method in accordance with CLSI recommendations.

Results.

The prevalence of MRSA among tested strains was 49.9% and varied from 0 to 83% in different hospitals. The most potent antimicrobials were linezolid, vancomycin and mupirocin to which no resistance was found. The other antimicrobials with low frequency of resistance were fusidic acid and co-trimoxazole (0.4% of intermediate and 3% resistant strains, respectively). Fluoroquinolones have shown low activity. The high rates of resistance were found in to erythromycin (46,8%), gentamicin (45,4%), tetracycline (42,3%), lincomycin (41%) and clindamycin (39,9%).

Conclusions.

Linezolid and vancomycin can be used as the drugs of choice for the treatment of S.aureus ICU infections in Russian hospitals. High rates of resistance to macrolides, lyncosamides, β-lactams, tetracycline and aminiglicosides advise not to use these antimicrobials for empiric therapy of S.aureus infections in ICU.

  • 1. Jevons M.P. Celebin-resistant staphylococci. BMJ 1961; 1: 124-5.
  • 2. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32: 470–85.
  • 3. Страчунский Л.С., Дехнич А.В., Белькова Ю.А. Сравнительная активность антибактериальных препаратов, входящих в лекарственные формы для местного применения, в отношении Staphylo­coccus aureus: результаты российского многоцентро­вого исследо­вания. Клин микробиол антимикроб химиотер 2002; 4(2): 157-63.
  • 4. Liu C., Chambers H.F. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003; 47:3040-5.
  • 5. Chang S., Sievert D.M., Hageman J.C., et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348:1342-7.
  • 6. Tenover F.C., Weigel L.M., Appelbaum P.C., et al. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 2004; 48:275-80.
  • 7. Tiemersma E.W., Bronzwaer S.L., Lyytikainen O., et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis 2004; 10:1627-34.
  • 8. Vincent J-L., Bihari D.J., Suter P.M., et al. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) study. JAMA 1995; 274:639- 44.
  • 9. Hardy K.J., Hawkey P.M., Gao F., Oppenheim B.A. Methicillin resistant Staphylococcus aureus in the critically ill. Br J Anaesth 2004; 92:121-30.
  • 10. Hoefnagels-Schuermans A., Borremans A., Peetermans W., et al. Origin and transmission of methicillin resistant Staphylococcus aureus in an endemic situation: differences between geriatric and intensive care patients. J Hosp Infect 1997; 36:209-22.
  • 11. Ibelings M.M.S., Bruining H.A. Methicillin-resistant Staphylococcus aureus: acquisition and risk of death in patients in the intensive care unit. Eur J Surg 1998; 164:411-18.
  • 12. Law M.R., Gill O.N. Hospital acquired infection with methicillin-resistant and methicillin-sensitive staphylococci. Epidemiol Infect 1988; 101:623-9.
  • 13. Pujol M., Pena C., Pallares R., et al. Risk factors for nosocomial bacteraemia due to methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1994; 13:96-102.
  • 14. Merrer J., Santoli F., Vecchi C., et al. Colonization pressure and risk of acquisition of methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect Control Hosp Epidemiol 2000; 21:718-23.
  • 15. Tverdek F.P., Crank C.W., Segreti J. Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care. Crit Care Clin 2008; 24:249-60.
  • 16. Perfomance Standards for Antimicrobial Susceptibility Testing; Sixteenth Information Supplement M 100-S16. 2006; 26(3).
  • 17. Comite de l’antibiogramme de la societe francaise de microbiologie Communique 2006 (Edition de Janvier 2006).
  • 18. Богданович Т.М., Страчунский Л.С. Мупиро­цин: уникальный антибиотик для местного применения. Клин микробиол антимикроб химиотер 1999; 1(1):57-65.
  • 19. Kim M., Hwang S. H., Pyo Y. et al. Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a University Hospital in Korea. J Clin Microbiol 2002; 40:1376-80.
  • 20. Presterl E., Mueller-Uri P., Grisold A., et al. Ciprofloxacinand methicillin-resistant Staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid. Eur J Clin Microbiol Infect Dis 2001; 20:486-9.
  • 21. Henwood C.J., Livermore D.M., Johnson A.P., et al. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group. J Antimicrob Chemother 2000; 46:931-40.
  • 22. O’Neill A.J., Larsen A.R., Skov R., et al. Charac­terization of the epidemic european fusidic acid-resistant impetigo clone of Staphylococcus aureus. J Clin Microbiol 2007; 45:1505-10.
  • 23. Osterlund A., Eden T., Olsson-Liljequist B., et al. Clonal spread among Swedish children of a Staphylo­coccus aureus strain resistant to fusidic acid. Scand J Infect Dis 2002; 34:729-34.
  • 24. El-Zimaity D., Kearns A. M., Dawson S. J., et al. Survey, characterization and susceptibility to fusidic acid of Staphylococcus aureus in the Carmarthen area. J Antimicrob Chemother 2004; 54:441-6.
  • 25. Mason B.W., Howard A.J., Magee J.T. Fusidic acid resistance in community isolates of methicillin-susceptible Staphylococcus aureus and fusidic acid prescribing. J Antimicrob Chemother 2003; 51:1033-6.
  • 26. Turnidge J., Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents 1999; 12 (Suppl 2):35-44.
  • 27. Samra Z., Gadba R., Ofir O. Antibiotic susceptibility and phage typing of methicillin-resistant and -sensitive Staphylococcus aureus clinical isolates at the period during 1991-1997. Eur J Clin Microbiol Infect Dis 2001; 20:427-7.
  • 28. O’Neill A.J., Cove J.H., Chopra I. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. J Antimicrob Chemother 2001; 47:647-50.
  • 29. Rennie RP. Susceptibility of Staphylococcus aureus to fusidic acid: Canadian data. J Cutan Med Surg 2006;10:277-80.
  • 30. Peeters K.A., Mascini E.M., Blok H.E., et al. Increase in rate of resistance to fusidic acid among Staphylococcus aureus isolates from patients admitted with atopic dermatitis. Ned Tijdschr Geneeskd 2002; 46:2100-1.
  • 31. Upton A., Lang S., Heffernan H. Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance. J Antimicrob Chemother 2003; 51:613-7.
  • 32. Rossney A., O’Connell S. Emerging high-level mupirocin resistance among MRSA isolates in Ireland. Eurosurveillance 2008; 13(14).
  • 33. Orrett F. A. The emergence of mupirocin resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in Trinidad: a first report. Jpn J Infect Dis 2008; 61:107-10.
  • 34. Kochman M., Fordymacki P., Lawrynowicz-Paciorek M., et al. Susceptibility to selected chemotherapeutics of Staphylococcus aureus strains resistant to methicillin isolated from clinical materials in the years 1991-1992 and 1997. Med Dosw Mikrobiol 1999; 51:187-98.
  • 35. Pérez-Fontán M., Rosales M., Rodríguez-Car­mona A., et al. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002; 39:337-41.
  • 36. Yamaguchi K., Ohno A., Ishii Y., et al. In-vitro susceptibilites to levofloxacin and various antibacterial agents of 18,639 clinical isolates obtained from 77 centers in 2004. Jpn J Antibiot 2006; 59:428-51.
  • 37. Zhanel G.G., DeCorby M., Laing N., et al. Antimicrobialresistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob Agents Chemother 2008; 52:1430-7.
  • 38. Nishijima S., Kurokawa I. Antimicrobial resistance of Staphylococcus aureus isolated from skin infections. Int J Antimicrob Agents 2002; 19:241-3.
  • 39. Jorgensen J.H. Laboratory and epidemiologic experience with methicillin-resistant Staphylococcus aureus in the USA. Eur J Clin Microbiol 1986; 5:693-6.
  • 40. Guerin F., Buu-Hoi A., Mainardi J.-L., et al. Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Parisian hospital. J Clin Microbiol 2000; 38:2985-8.
  • 41. Rohani M.Y., Raudzah A., Lau M.G., et al. Susceptibility pattern of Staphylococcus aureus isolated in Malaysian hospitals. Int J Antimicrob Agents 2000; 13:209-13.
  • 42. Swarz M.N. Use of antimicrobial agents and drug resistance. N Engl J Med 1997; 337:491-2.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared